Emerging Company Profile: The Dutch biotech is working on a more streamlined autologous stem cell therapy for traumatic spinal cord injury, an indication currently dominated by allogeneic treatments which present safety issues.

The CNS-focused SK Group affiliate has set out ambitious growth plans for this year and is moving forward with a diversification into oncology and other areas, beginning its first US cancer trials in brain tumors and cancers with brain metastasis.

Hyloris expects to expand its portfolio to around 30 candidates by 2024, bolstered by €50m in cash and cash equivalents as of the end of 2021.

Heading into the J.P. Morgan Healthcare conference, pharmas have been focusing on discovery alliances. J&J’s deals look into novel tissue-targeted drugs, ionic liquid delivery technology and cancer vaccine R&D. Lilly teams with Entos on novel methods for delivering neurology drugs.